Rice Hall James & Associates’s Aurinia Pharmaceuticals AUPH Stock Holding History

Rice Hall James & Associates’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.07M	Sell	416,631 -71,267	-15%	-$1.14M	0.34%	77
2026 Q1	$7.23M	Sell	487,898 -7,738	-2%	-$113K	0.4%	65
2025 Q4	$7.91M	Sell	495,636 -46,919	-9%	-$665K	0.44%	61
2025 Q3	$6M	Sell	542,555 -7,946	-1%	-$86.8K	0.33%	75
2025 Q2	$4.66M	Buy	550,501 +325,031	+144%	+$2.61M	0.25%	85
2025 Q1	$1.81M	Buy	+225,470	New	+$1.83M	0.11%	168

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rice Hall James & Associates's AUPH Position: Q2 2026 in Review

Rice Hall James & Associates reduced its Aurinia Pharmaceuticals (AUPH) stake by 15% in Q2 2026, selling an estimated $1.14M and leaving 416,631 shares worth $7.07M. The position accounts for 0.34% of the portfolio, ranked #77.

Rice Hall James & Associates first reported a position in AUPH in Q1 2025 and has held it in 6 quarters since. The position peaked at $7.91M in Q4 2025. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Rice Hall James & Associates held 416,631 shares of Aurinia Pharmaceuticals worth $7.07M as of Q2 2026.
Rice Hall James & Associates sold 71,267 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $1.14M.
Aurinia Pharmaceuticals made up 0.34% of Rice Hall James & Associates's portfolio in Q2 2026, its #77 holding.
Rice Hall James & Associates first reported a position in Aurinia Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Rice Hall James & Associates's Aurinia Pharmaceuticals position peaked at $7.91M in Q4 2025.
282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.